An initiative to reduce wait times for spinal cord surgery, research that is testing ways to inhibit brain cancer cells, an open database for multiple sclerosis and an app that tracks Alzheimer’s progression and aids diagnosis. All these projects and more were made possible by a campaign that has raised $203.9 million for groundbreaking neuroscience research and patient care.
A diagnosis is often a cue for people to change the way they live. For people diagnosed with cardiovascular conditions such as heart disease or diabetes, it is often a motivator to get more physical exercise, which can improve long-term health. However, the rate of physical activity increase after diagnosis varies widely depending on the individual.
A surgical device powered by artificial intelligence (AI) was demonstrated live for the first time at The Neuro (Montreal Neurological Institute-Hospital) in a historic step forward for the field of precision neurosurgery. SENTRY™, an innovative technology developed by Montreal-based Reveal and its university partners, can differentiate cancerous tissue from healthy tissue in real time, offering tangible hope to patients for better outcomes.
A groundbreaking project led by Dr. Pedro Rosa-Neto at The Neuro (Montreal Neurological Institute-Hospital) of McGill University has received a major boost thanks to a $10-million grant from the Weston Family Foundation.
The funding is part of a $20-million initiative by the foundation to support highly ambitious scientific endeavors under its Healthy Aging Strategy, comprised of the Weston Brain Institute and the Weston Family Microbiome Initiative.
We take our understanding of where we are for granted, until we lose it. When we get lost in nature or a new city, our eyes and brains kick into gear, seeking familiar objects that tell us where we are.
How our brains distinguish objects from background when finding direction, however, was largely a mystery. A new study provides valuable insight into this process, with possible implications for disorientation-causing conditions such as Alzheimer’s.
Sylvain Baillet, PhD, a global leader in brain imaging and systems neuroscience, has been inducted into the Royal Society of Canada, one of the nation’s highest academic honours.
Artificial intelligence (AI) is becoming a powerful new tool in training and education, including in the field of neurosurgery. Yet a new study suggests that AI tutoring provides better results when paired with human instruction.
Original article by The Neuro.
A career that took an uncharted trajectory has been recognized with the Order of Canada, one of the country’s top honours.
A career that took an uncharted trajectory has been recognized with the Order of Canada, one of the country’s top honours.
Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
A healthcare telementoring program housed at The Neuro and supported by the Transforming Autism Care Consortium (TACC) is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.
Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.
A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and Martine Tétreault, PhD, at Université de Montréal has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.
